$0.16 EPS Expected for AngioDynamics, Inc. (ANGO) This Quarter

Equities analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to post earnings per share of $0.16 for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for AngioDynamics’ earnings, with estimates ranging from $0.15 to $0.16. AngioDynamics posted earnings of $0.19 per share during the same quarter last year, which would suggest a negative year over year growth rate of 15.8%. The company is scheduled to report its next quarterly earnings results on Wednesday, July 12th.

On average, analysts expect that AngioDynamics will report full year earnings of $0.69 per share for the current year, with EPS estimates ranging from $0.69 to $0.70. For the next financial year, analysts expect that the company will post earnings of $0.68 per share, with EPS estimates ranging from $0.66 to $0.70. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that follow AngioDynamics.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Thursday, March 30th. The medical instruments supplier reported $0.19 EPS for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.04. The firm earned $85.60 million during the quarter, compared to the consensus estimate of $88.29 million. AngioDynamics had a positive return on equity of 4.87% and a negative net margin of 7.91%. The firm’s revenue was down 2.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.15 EPS.

ANGO has been the topic of a number of research analyst reports. Cantor Fitzgerald set a $21.00 target price on AngioDynamics and gave the company an “overweight” rating in a report on Thursday, April 6th. Canaccord Genuity reaffirmed a “hold” rating and issued a $17.50 target price on shares of AngioDynamics in a report on Monday, January 23rd. Zacks Investment Research lowered AngioDynamics from a “buy” rating to a “hold” rating in a report on Monday, April 10th. Finally, Barclays PLC initiated coverage on AngioDynamics in a report on Wednesday, February 8th. They issued an “equal weight” rating and a $17.00 target price on the stock. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $18.75.

In other AngioDynamics news, major shareholder Avista Capital Partners Gp, Ll sold 2,350,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 12th. The stock was sold at an average price of $16.00, for a total value of $37,600,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.88% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Municipal Employees Retirement System of Michigan increased its stake in shares of AngioDynamics by 7.3% in the third quarter. Municipal Employees Retirement System of Michigan now owns 6,330 shares of the medical instruments supplier’s stock worth $111,000 after buying an additional 430 shares in the last quarter. Old Mutual Global Investors UK Ltd. purchased a new stake in shares of AngioDynamics during the first quarter worth approximately $164,000. Louisiana State Employees Retirement System increased its stake in shares of AngioDynamics by 2.4% in the first quarter. Louisiana State Employees Retirement System now owns 13,000 shares of the medical instruments supplier’s stock worth $226,000 after buying an additional 300 shares in the last quarter. Boothbay Fund Management LLC purchased a new stake in shares of AngioDynamics during the fourth quarter worth approximately $233,000. Finally, New York State Teachers Retirement System increased its stake in shares of AngioDynamics by 3.4% in the fourth quarter. New York State Teachers Retirement System now owns 15,086 shares of the medical instruments supplier’s stock worth $255,000 after buying an additional 500 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Shares of AngioDynamics (NASDAQ:ANGO) traded up 1.57% on Thursday, reaching $15.52. The company had a trading volume of 382,762 shares. The firm’s market capitalization is $570.83 million. AngioDynamics has a 12 month low of $11.52 and a 12 month high of $18.18. The company’s 50-day moving average is $16.42 and its 200 day moving average is $16.58.

ILLEGAL ACTIVITY NOTICE: “$0.16 EPS Expected for AngioDynamics, Inc. (ANGO) This Quarter” was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://transcriptdaily.com/2017/05/20/0-16-eps-expected-for-angiodynamics-inc-ango-this-quarter-updated-updated.html.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

5 Day Chart for NASDAQ:ANGO

Get a free copy of the Zacks research report on AngioDynamics (ANGO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply